春季易发的9种过敏性皮肤病

2022-03-29 药店网校 药店网校

春天来了,春暖花开,阳光明媚。但是有些皮肤病也随之而来,折磨着很多人。我们一起来看下春季有哪些易发的皮肤病呢?

春天来了,春暖花开,阳光明媚。但是有些皮肤病也随之而来,折磨着很多人。我们一起来看下春季有哪些易发的皮肤病呢?

湿疹 

湿疹是一种常见病,是由多种内、外因素引起的皮肤炎症,其病因复杂,一般认为与变态反应有关。

 
1.症状:皮疹多形性、瘙痒剧烈,急性期以丘疱疹为主,有渗出倾向,慢性期以苔藓样变为主,易反复发作。皮肤损害表现为多形性,即红斑、丘疹、丘疱疹、水疱、糜烂、渗出、结痂、脱屑等各种皮疹可互见。
 
1)急性湿疹:皮疹表现为密集的针头到粟粒大小的丘疹、丘疱疹,严重时有小水疱,常融合成片,境界不清楚,分布对称;多见于面、耳、手、足、前臂、小腿等外露部位,严重者可弥漫全身;自觉瘙痒较重,常因搔抓形成点状糜烂面,有明显浆液性渗出。总之皮疹潮红肿胀等急性炎症明显;(如图1)
 
2)亚急性湿疹:经急性发作后,红肿及渗出减轻,皮疹呈暗红色,可有少许鳞屑,自觉剧烈瘙痒;
 
3)慢性湿疹:由急性湿疹及亚急性湿疹迁延而成,皮肤肥厚,粗糙,呈苔藓样变,多有色素沉着或色素减退,好发于手、足、小腿、肘窝、股部、乳房、外阴、肛门等处,多对称发病。(如图2)
 
图片

 

2.特点:可发生于任何年龄段,任何季节;皮疹可发生于体表的任何部位,最易发的部位是头面、耳后、四肢、手足、阴囊、肛门等。
 
3.病因:近年来湿疹发病率明显上升,这可能与化学制品滥用、环境污染、生活节奏加快、精神压力加大等因素有关。
 
4.鉴别:
1)慢性湿疹和神经性皮炎:后者多见于颈项、肘和尾骶部,主要皮疹为苔藓样变,无多形性皮疹,无渗出。
 
2)手足湿疹和手足癣:手足癣皮损为单侧发生,皮疹边界清楚,有鳞屑附着,常在夏季加重。
 
5.治疗:
口服药:敏迪,维生素B族,维生素C,及钙,还可以口服荨麻疹丸,中药制剂副作用小,而且中药制剂可以有整体调节的功效,有利于慢性病的有效治疗。
 
外用药:丹皮酚、曲咪新软膏、皮炎平、艾洛松。

 

药疹

药疹又称药物性皮炎,是药物通过口服、注射、吸入、栓剂吸收、外用透皮吸收等途径进入人体后引起的皮肤黏膜反应。

可以引起药疹的药物很多,最常见的有抗生素类药、磺胺类药、镇静药和解热镇痛药、异种血清制剂及疫苗等。

1.症状:

1)固定红斑型:这是最常见的一型。好发于手足背及皮肤黏膜交界处,如口唇、外生殖器、肛门等处。

皮疹特点是圆形或椭圆形的水肿性紫红斑,直径一般1~2cm或更大,境界清楚,多数是单发,少数也可多发,紫红斑中央可出现水疱或大疱,持续7~10天,消退后留有暗褐色或棕褐色色素沉着斑,可持续数月或更长时间。自觉症状仅有轻度痒感及灼痛感。

如再次用致敏药物,又会在原处发生同样皮疹,随着复发次数增加,皮损数目亦可增多,面积可扩大。反复发作后,遗留的色素沉着斑不易消退。

2)荨麻疹性药疹:较常见。症状与急性荨麻疹相似,但风团颜色较鲜红,皮疹持续时间较长。严重的可伴有发热、关节痛、淋巴结肿大、血管性水肿和蛋白尿等。

图片

3)麻疹样或猩红热样型:皮肤上出现弥漫性鲜红色斑或半米粒大的红色斑丘疹,皮疹主要分布于躯干,可泛发全身,类似麻疹或猩红热。

4)多形红斑型:特点是豌豆大至蚕豆大圆形或椭圆形水肿性红斑或丘疹,中央常有水疱,对称发生于四肢伸侧、躯干,境界清楚,有痛痒感。重症病人的口、眼、外阴黏膜会发生水疱糜烂,剧烈疼痛。 

5)大疱性表皮松解型,这是药疹中最严重的一型

可发生于任何年龄,起病急骤,全身中毒症状明显,皮肤出现弥漫性紫红或暗红斑片,并很快出现松弛性水疱、大疱及表皮大片松解脱落,疱壁易被撕破和脱落,露出糜烂面,渗液较多。

 同时有高热、疲乏、咽痛、呕吐、腹泻等症状,容易继发感染,发生肝肾功能障碍,电解质紊乱或内脏出血。此病死亡率高,应当送患者及时就医。

2.特点:任何一种药物,包括保健品在内都可能引起药疹。

3.病因:可以引起药疹的药物很多,最常见的有抗生素类药、磺胺类药、镇静药和解热镇痛药、异种血清制剂及疫苗等。 

4.鉴别:

1)麻疹样或猩红热样型药疹与麻疹或猩红热

区别是麻疹或猩红热没有近期用药史,并且出现皮疹前有上呼吸道症状(感冒,流涕,咳嗽,头痛等);而麻疹样或猩红热样型药疹没有上呼吸道症状,且有近期用药史。

如果在发病前20天内使用了以前未用过的药物,或以前用过但此时服用时药物已过期,或此次服用的和以前的非同一药厂生产,就可诊断为药疹; 

2)多形红斑型药疹与多形红斑:区别在于后者无近期用药史。

5.治疗:

局部治疗可使用:炉甘石洗剂、氧化锌软膏、外用糖皮质激素制剂、外用抗菌药制剂等。

口服药物可选择:抗组胺药、口服激素、雷公藤多甙片。

荨麻疹 

荨麻疹,俗称“风疹块”,是由于皮肤、黏膜小血管反应性扩张及渗透性增加而出现的一种局限性水肿反应,产生红斑和风团,伴瘙痒。

 荨麻疹的病因复杂,约3/4的患者找不到原因。其常见类型有急性和慢性两种。

1.症状:

1)急性荨麻疹:皮疹为大小不等的红色或苍白色风团,风团大小和形态不一,发作时间不定,数小时内风团可出现或消失。

部分患者可伴有恶心、呕吐等症状,甚至出现喉头水肿、呼吸困难或窒息。

2)慢性荨麻疹:全身症状一般较轻,风团时多时少,反复发生,病程在6周以上。  

2.特点:花粉诱发的荨麻疹,春季多发。

3.病因:病因复杂,约3/4的患者找不到原因。但空气中的花粉、尘螨等是重要的诱因。

4.鉴别:注意与荨麻疹性血管炎、丘疹性荨麻疹鉴别。

5.治疗:去除可能的诱因,长期反复者,最好查过敏原,针对性避免或脱敏治疗;口服抗组胺药;严重者必要时使用激素或免疫抑制剂。

4   季节性面部皮炎

为一种好发于春季,由花粉等引起的皮炎。多见于女性。 

1.症状:颜面、颈部轻度红斑、丘疹、肿胀,伴瘙痒,严重的可出现渗液,后期可皮肤轻度肥厚,有脱屑。

2.特点:春季好发,每年反复发生,轻者过了春季可自行消退。有些人伴有过敏性鼻炎或哮喘等。

3.病因:空气中的花粉。可查过敏原明确。

4.鉴别:需要与化妆品皮炎及日光性皮炎鉴别。

5.治疗:应注意皮肤的清洁、保湿;对症抗过敏治疗;如长期反复发生,比较严重的,最好查过敏原,针对性脱敏治疗。

日光性皮炎 

是一种常见的对日光中紫外线过敏的疾病,好发于春季和夏初。

1.症状:在曝光部位出现境界清楚的红斑,鲜红色;随后红斑颜色变暗、脱屑,留有色素沉着或减退。自觉烧灼感或刺痛感,常影响睡眠。 

2.特点:主要分布于面、颈及手背等暴露部位,一般在日晒后数小时或数天出现。

3.病因:日光中的紫外线。可做光敏试验明确。

4.鉴别:注意与接触性皮炎和红斑狼疮鉴别。

5.治疗:防晒;对症抗炎治疗;可口服硫酸羟氯喹抗光敏;尽量避免吃光敏性食物或药物,如香椿、香菜、芹菜、黄泥螺、皮皮虾、磺胺、四环素类药物等。

激素依赖性皮炎 

由长期不恰当使用外用软膏的激素引起,因为症状类似吸毒成瘾,停用后皮炎反复加重,又称为激素成瘾性皮炎、激素戒断皮炎。

1.症状:皮肤出现明显鲜红色斑,表面光滑、变薄、毛细血管扩张、干燥、脱屑等。遇热症状加重。 

2.特点:最常见于面部,多数有刺痛、烧灼和瘙痒感。

3.病因:长期反复外用激素≥1月。

特别小心:有些不正规的面膜或护肤品中含有激素,这些产品的特点就是短期内效果奇好。

4.鉴别:需要和口周皮炎、激素过敏及原发皮肤病停药复发鉴别。

5.治疗:

停用一切外用激素;

保湿:增加角质层内水分,恢复皮肤屏障;

抗炎:局部外用免疫调节剂,如他克莫司软膏、吡美莫司软膏,口服抗组胺药,如氯雷他定片或依巴斯汀片等。

如继发感染,需要同时使用抗生素。

7化妆品皮炎 

是指由化妆品刺激或过敏引起的皮肤病。 

1.症状:出现红斑、丘疹,严重者出现水疱、渗液,自觉瘙痒。

2.特点:常见于面部使用化妆品的部位,停用后缓解,再次使用复发。

3.病因:对化妆品中的一些成分过敏,如肉桂醛、苯甲醇、熏衣草油、依兰油、颜料、香精等。必要时可以做斑贴试验明确过敏原。

4.鉴别:根据明确的化妆品接触史可与其他过敏性皮炎区别。

5.治疗:停用并及时清除皮肤残留的引起过敏的化妆品;抗过敏治疗;可使用适合敏感皮肤的医学护肤品。

 

丘疹性荨麻疹(虫咬性皮炎) 

是由昆虫叮咬皮肤引起的过敏性皮肤病,又称虫咬性皮炎、单纯性痒疹,春秋多见。

常分批发生于躯干、四肢伸侧,自觉瘙痒。皮损为红色风团样丘疹,呈纺锤形或圆形,中央常有丘疱疹、水疱或大疱。

1.症状:局部红肿,常呈梭形,表面可出现水疱及大疱,皮损中心有时可见叮咬痕迹。自觉奇痒,有时有刺痛、灼疼。

2.特点:尽管成人也可发生,但最常见于儿童,而且比较重。

3.病因:常由蚊、白蛉、蠓、蚋、臭虫、蚤、虱、螨虫及其他昆虫叮咬引起。

4.鉴别:注意和荨麻疹鉴别:后者多发于夏秋季节,儿童尤多,为风团样丘疹性皮疹,可与某些昆虫如蚊虫、螨、跳蚤、臭虫等叮咬有关,且风团样丘疹不会时起时消。

5.治疗:

注意个人及环境卫生,对于易发生本病的患者,在春秋季节尽量少到花草多的地方;

一般可外用炉甘石洗剂、激素软膏,合并感染时可给予抗菌素。

有全身症状可用抗组胺药物,如果非常严重,必要时使用激素治疗。

接触性皮炎 

接触性皮炎是皮肤或黏膜接触某种物质后,在接触部位发生的急性或慢性炎症反应。

1.症状:主要表现为红斑,肿胀,丘疹,水疱,甚至大疱。急性接触性皮炎皮疹只局限于接触部位,并且皮疹形状与接触物形状一致。如果接触物为长方形,其边界很清楚。 

2.特点:只局限于接触部位,并且皮疹形状与接触物形状一致。去除接触物,适当处理后皮损一般很快消退。 

3.病因:能引发接触性皮炎的物质有很多种,可分为动物性、植物性和化学性三大类。在医院,斑贴试验是诊断接触性皮炎的最简单可靠的方法。

1)动物性物质包括动物毒素,如昆虫分泌物、毒毛等;

2)植物性物质包括花粉、叶、茎、花及果实等;

3)化学性物质是引起接触性皮炎的主要原因,主要有金属及其制品、塑料、橡胶、香料等。

4.鉴别:

1)接触性皮炎与急性湿疹:急性湿疹的病因一般不明确,发病常呈泛发性,损害呈多形性,病程较长,且有复发倾向。急性接触性皮炎的接触史明显,病变局限于接触部位,皮疹形状与接触物形状一致,搔抓后可将致病物质带到远隔部位并产生类似皮损。

2)面部接触性皮炎与皮肌炎:后者多发生于双上睑,为水肿性紫红,伴有全身无力症状和肌酶谱升高等。

5.治疗:

口服药:抗组织胺药类:皿治林、氯雷他定、西替利嗪、荨麻疹丸。

外用药:丹皮酚、曲咪新软膏、艾洛松、皮炎平。

联合用药:维生素C或B族、钙剂、氨基酸软胶囊、氧氟沙星凝胶。

常见治疗方法

①轻度皮肤过敏

如果只有轻微的红斑、少量细小鳞屑,无明显水肿,瘙痒不明显者,只需尽量避免诱发因素,同时使用医学护肤品的保湿舒敏系列产品,可以不用药物。

②中度皮肤过敏:

有红斑、丘疹、水肿,伴明显瘙痒者,可短期使用激素软膏,如丁酸氢化可的松软膏、地奈德软膏或糠酸莫米松乳膏,但连续使用最好不超过2周,而且应在病情好转后逐渐减量停药。

如果长期反复发生,则最好外用免疫调节剂,如0.03%他克莫司软膏或吡美莫司软膏。可口服抗组胺药,如氯雷他啶片或依巴斯汀片等,也可配合使用复方甘草酸苷片。

③重度皮肤过敏:

除了中度过敏的症状,还出现水疱和流黄水。则需要用2%硼酸溶液或生理盐水冷敷,将4~6层纱布浸湿拧干,以不滴水为度,敷于面部红斑处。

湿敷时保持纱布冷湿,每次15~20分钟,每天2~3天。冷敷后短期使用激素类软膏或免疫调节剂软膏(同前)。

如果一般抗过敏药效果不佳,需要短期全身使用激素,一定要注意药物的不良反应。如继发感染,则需要口服或外用抗生素。

④荨麻疹:应以口服抗组胺药为主,一般没有必要外用药。

⑤丘疹性荨麻疹(虫咬性皮炎):应以外用药为主,严重的可配合口服药。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826168, encodeId=234d18261689c, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 11 21:47:18 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047467, encodeId=8012204e46728, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 27 13:47:18 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090242, encodeId=88d12090242d2, content=学习了<a href='/topic/show?id=45979402e97' target=_blank style='color:#2F92EE;'>#过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94027, encryptionId=45979402e97, topicName=过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15086547838, createdName=ms2000001843522165, createdTime=Sun Sep 25 08:49:55 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216325, encodeId=7c3a12163257b, content=学习并收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19a52601958, createdName=151263872, createdTime=Mon May 02 15:21:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209139, encodeId=647c12091394c, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e06a6525385, createdName=ms4000000065127311, createdTime=Thu Apr 07 07:25:15 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207689, encodeId=ea79120e6890c, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba35380245, createdName=ms7000001725184531, createdTime=Thu Mar 31 22:41:59 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206913, encodeId=53b3120691375, content=学习<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Mar 29 15:06:49 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206911, encodeId=fc7f12069115d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8715510311, createdName=ms8000001609354510, createdTime=Tue Mar 29 15:05:32 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826168, encodeId=234d18261689c, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 11 21:47:18 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047467, encodeId=8012204e46728, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 27 13:47:18 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090242, encodeId=88d12090242d2, content=学习了<a href='/topic/show?id=45979402e97' target=_blank style='color:#2F92EE;'>#过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94027, encryptionId=45979402e97, topicName=过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15086547838, createdName=ms2000001843522165, createdTime=Sun Sep 25 08:49:55 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216325, encodeId=7c3a12163257b, content=学习并收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19a52601958, createdName=151263872, createdTime=Mon May 02 15:21:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209139, encodeId=647c12091394c, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e06a6525385, createdName=ms4000000065127311, createdTime=Thu Apr 07 07:25:15 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207689, encodeId=ea79120e6890c, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba35380245, createdName=ms7000001725184531, createdTime=Thu Mar 31 22:41:59 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206913, encodeId=53b3120691375, content=学习<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Mar 29 15:06:49 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206911, encodeId=fc7f12069115d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8715510311, createdName=ms8000001609354510, createdTime=Tue Mar 29 15:05:32 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826168, encodeId=234d18261689c, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 11 21:47:18 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047467, encodeId=8012204e46728, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 27 13:47:18 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090242, encodeId=88d12090242d2, content=学习了<a href='/topic/show?id=45979402e97' target=_blank style='color:#2F92EE;'>#过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94027, encryptionId=45979402e97, topicName=过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15086547838, createdName=ms2000001843522165, createdTime=Sun Sep 25 08:49:55 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216325, encodeId=7c3a12163257b, content=学习并收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19a52601958, createdName=151263872, createdTime=Mon May 02 15:21:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209139, encodeId=647c12091394c, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e06a6525385, createdName=ms4000000065127311, createdTime=Thu Apr 07 07:25:15 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207689, encodeId=ea79120e6890c, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba35380245, createdName=ms7000001725184531, createdTime=Thu Mar 31 22:41:59 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206913, encodeId=53b3120691375, content=学习<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Mar 29 15:06:49 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206911, encodeId=fc7f12069115d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8715510311, createdName=ms8000001609354510, createdTime=Tue Mar 29 15:05:32 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-09-25 ms2000001843522165

    学习了#过敏#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1826168, encodeId=234d18261689c, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 11 21:47:18 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047467, encodeId=8012204e46728, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 27 13:47:18 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090242, encodeId=88d12090242d2, content=学习了<a href='/topic/show?id=45979402e97' target=_blank style='color:#2F92EE;'>#过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94027, encryptionId=45979402e97, topicName=过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15086547838, createdName=ms2000001843522165, createdTime=Sun Sep 25 08:49:55 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216325, encodeId=7c3a12163257b, content=学习并收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19a52601958, createdName=151263872, createdTime=Mon May 02 15:21:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209139, encodeId=647c12091394c, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e06a6525385, createdName=ms4000000065127311, createdTime=Thu Apr 07 07:25:15 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207689, encodeId=ea79120e6890c, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba35380245, createdName=ms7000001725184531, createdTime=Thu Mar 31 22:41:59 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206913, encodeId=53b3120691375, content=学习<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Mar 29 15:06:49 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206911, encodeId=fc7f12069115d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8715510311, createdName=ms8000001609354510, createdTime=Tue Mar 29 15:05:32 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-05-02 151263872

    学习并收藏了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1826168, encodeId=234d18261689c, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 11 21:47:18 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047467, encodeId=8012204e46728, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 27 13:47:18 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090242, encodeId=88d12090242d2, content=学习了<a href='/topic/show?id=45979402e97' target=_blank style='color:#2F92EE;'>#过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94027, encryptionId=45979402e97, topicName=过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15086547838, createdName=ms2000001843522165, createdTime=Sun Sep 25 08:49:55 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216325, encodeId=7c3a12163257b, content=学习并收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19a52601958, createdName=151263872, createdTime=Mon May 02 15:21:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209139, encodeId=647c12091394c, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e06a6525385, createdName=ms4000000065127311, createdTime=Thu Apr 07 07:25:15 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207689, encodeId=ea79120e6890c, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba35380245, createdName=ms7000001725184531, createdTime=Thu Mar 31 22:41:59 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206913, encodeId=53b3120691375, content=学习<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Mar 29 15:06:49 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206911, encodeId=fc7f12069115d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8715510311, createdName=ms8000001609354510, createdTime=Tue Mar 29 15:05:32 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-04-07 ms4000000065127311

    受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1826168, encodeId=234d18261689c, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 11 21:47:18 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047467, encodeId=8012204e46728, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 27 13:47:18 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090242, encodeId=88d12090242d2, content=学习了<a href='/topic/show?id=45979402e97' target=_blank style='color:#2F92EE;'>#过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94027, encryptionId=45979402e97, topicName=过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15086547838, createdName=ms2000001843522165, createdTime=Sun Sep 25 08:49:55 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216325, encodeId=7c3a12163257b, content=学习并收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19a52601958, createdName=151263872, createdTime=Mon May 02 15:21:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209139, encodeId=647c12091394c, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e06a6525385, createdName=ms4000000065127311, createdTime=Thu Apr 07 07:25:15 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207689, encodeId=ea79120e6890c, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba35380245, createdName=ms7000001725184531, createdTime=Thu Mar 31 22:41:59 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206913, encodeId=53b3120691375, content=学习<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Mar 29 15:06:49 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206911, encodeId=fc7f12069115d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8715510311, createdName=ms8000001609354510, createdTime=Tue Mar 29 15:05:32 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-03-31 ms7000001725184531

    学习#学习#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1826168, encodeId=234d18261689c, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 11 21:47:18 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047467, encodeId=8012204e46728, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 27 13:47:18 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090242, encodeId=88d12090242d2, content=学习了<a href='/topic/show?id=45979402e97' target=_blank style='color:#2F92EE;'>#过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94027, encryptionId=45979402e97, topicName=过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15086547838, createdName=ms2000001843522165, createdTime=Sun Sep 25 08:49:55 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216325, encodeId=7c3a12163257b, content=学习并收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19a52601958, createdName=151263872, createdTime=Mon May 02 15:21:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209139, encodeId=647c12091394c, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e06a6525385, createdName=ms4000000065127311, createdTime=Thu Apr 07 07:25:15 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207689, encodeId=ea79120e6890c, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba35380245, createdName=ms7000001725184531, createdTime=Thu Mar 31 22:41:59 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206913, encodeId=53b3120691375, content=学习<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Mar 29 15:06:49 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206911, encodeId=fc7f12069115d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8715510311, createdName=ms8000001609354510, createdTime=Tue Mar 29 15:05:32 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1826168, encodeId=234d18261689c, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 11 21:47:18 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047467, encodeId=8012204e46728, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 27 13:47:18 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090242, encodeId=88d12090242d2, content=学习了<a href='/topic/show?id=45979402e97' target=_blank style='color:#2F92EE;'>#过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94027, encryptionId=45979402e97, topicName=过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15086547838, createdName=ms2000001843522165, createdTime=Sun Sep 25 08:49:55 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216325, encodeId=7c3a12163257b, content=学习并收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19a52601958, createdName=151263872, createdTime=Mon May 02 15:21:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209139, encodeId=647c12091394c, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e06a6525385, createdName=ms4000000065127311, createdTime=Thu Apr 07 07:25:15 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207689, encodeId=ea79120e6890c, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba35380245, createdName=ms7000001725184531, createdTime=Thu Mar 31 22:41:59 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206913, encodeId=53b3120691375, content=学习<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Mar 29 15:06:49 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206911, encodeId=fc7f12069115d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8715510311, createdName=ms8000001609354510, createdTime=Tue Mar 29 15:05:32 CST 2022, time=2022-03-29, status=1, ipAttribution=)]
    2022-03-29 ms8000001609354510

    好好学习

    0

相关资讯

Br J Dermatol:增强角质层脂质结构可改善成人干燥、易患湿疹皮肤的皮肤屏障功能并保护其免受刺激

特应性皮炎(AD)患者的皮肤以角质层(SC)脂质水平异常为特征。因此,板层基质被破坏,皮肤屏障功能减弱,增加了皮肤对刺激物和过敏原的敏感性。

JEADV:DUPILUMA治疗伴有STAT3高免疫球蛋白E综合征的儿童湿疹

该研究表明,dupilumab是治疗STAT3-HIE儿童皮损的有效和安全的治疗选择。减少给药频率可能是一种有价值的治疗策略,特别是对于经常害怕注射的儿科患者。

Clin Exp Allergy:个体参与者数据荟萃分析与汇总数据荟萃分析:湿疹和食物过敏预防的案例研究

荟萃分析是循证决策的基础,它将多个相关研究的定量结果结合起来,总结出关于特定临床问题的所有可用证据,在这篇文章中,我们调查了进行IPD荟萃分析的潜在附加值。

JAAD:滤泡性湿疹相关介绍

滤泡性湿疹或滤泡性特应性皮炎的主要特征是滤泡明显瘙痒,通常在胸部、背部、腹部和两侧,进一步的研究将可能包括为这种疾病和受影响人群制定一个具体的严重程度评分。

JAAD:湿疹患者紫外线光疗会增加皮肤癌的发生率吗?

除了有免疫抑制治疗史的患者外,接受UVB光疗(包括窄波段UVB、宽带UVB和UVAB)的患者患黑素瘤、鳞状细胞癌和基底细胞癌的风险没有增加,支持这一疗法对AE患者的非致癌治疗。

JAAD:益生菌可以治疗湿疹吗?

湿疹是一种儿童和成人常见的炎症性皮肤疾病,以非传染性慢性瘙痒炎症为特征。该文表明目前使用益生菌治疗湿疹可能没有有力的数据支撑,同时也证实了最近的治疗建议。